Full year 2010 sales and significant developments

February 3, 2011
Disclaimer

This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated in the summary information. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably given that a new product can appear to be promising at a preparatory stage of development or after clinical trials but never be launched on the market or be launched on the market but fail to sell notably for regulatory or competitive reasons. The Group must deal with or may have to deal with competition from generic that may result in market share losses, which could affect its current level of growth in sales or profitability. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this presentation to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based unless so required by applicable law.

All product names listed in this document are either licensed to the Ipsen Group or are registered trademarks of the Ipsen Group or its partners.
2010 drug sales in line with objectives driven by Specialty Care…

Group sales by therapeutic area

+5.0%

In million euros

<table>
<thead>
<tr>
<th>2009 A</th>
<th>2010 A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Others</td>
<td>30.2</td>
</tr>
<tr>
<td>Primary care</td>
<td>380.1</td>
</tr>
<tr>
<td>Specialty care</td>
<td>622.5</td>
</tr>
<tr>
<td>Others</td>
<td>31.9</td>
</tr>
<tr>
<td>Primary care</td>
<td>364.0</td>
</tr>
<tr>
<td>Specialty care</td>
<td>704.3</td>
</tr>
</tbody>
</table>

Specialty care: dynamic growth in all geographies

Primary care: tougher competitive environment in France

All growth rates exclude foreign exchange impacts
... and regions beyond European G5

GROUP SALES by region
(incl. Drug related sales)

+5.0%

- European G5
  Specialty care sales growth offset by tougher competitive environment, notably in French Primary care

- Other European countries
  Dynamic growth throughout; favourable 2009 basis (Eastern Europe crisis)

- North America
  Strong growth driven by the penetration of 4 products

- ROW
  Strong growth, notably in China with the launch of Decapeptyl® 3M in the treatment of prostate cancer

All growth rates exclude foreign exchange impacts
Specialty products account for 66% of total drug sales in 2010

*in million euros*

<table>
<thead>
<tr>
<th>Specialty care</th>
<th>Drug Sales</th>
<th>Growth Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decapeptyl</td>
<td>270.2</td>
<td>+7.7%</td>
</tr>
<tr>
<td>Dysport</td>
<td>183.7</td>
<td>+7.7%</td>
</tr>
<tr>
<td>Somatuline</td>
<td>170.0</td>
<td>+18.8%</td>
</tr>
<tr>
<td>NutropinAq</td>
<td>48.4</td>
<td>+18.2%</td>
</tr>
<tr>
<td>Increlex</td>
<td>26.1</td>
<td>+19.5%</td>
</tr>
<tr>
<td>Apokyn</td>
<td>6.0</td>
<td>+0.6%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Primary care</th>
<th>Drug Sales</th>
<th>Growth Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smecta</td>
<td>101.3</td>
<td>(1.3%)</td>
</tr>
<tr>
<td>Tanakan</td>
<td>96.4</td>
<td>(10.7%)</td>
</tr>
<tr>
<td>Nisis/co</td>
<td>55.1</td>
<td>(1.5%)</td>
</tr>
<tr>
<td>Forlax</td>
<td>38.9</td>
<td>(14.9%)</td>
</tr>
</tbody>
</table>

**SPECIALTY CARE**
- €704.3m
- +11.0%

**DRUG SALES**
- €1,068.3m
- +5.1%

**PRIMARY CARE**
- €364.0m
- (4.8%)

*All growth rates exclude foreign exchange impacts*
Ipsen could record non-cash and non-recurring impairment charges

On the basis of currently available information, notably:

- available sales and clinical programme forecast assumptions for certain of its businesses, notably its short-stature franchise in the United States
- and
- recent uncertainties in some of the Group’s partnerships development timelines

Indications of impairment...

1. ...lead the Group to run impairment tests...
2. ...that could result in the recording of the depreciation of some of the Group’s intangible and deferred tax assets.

A total non-cash and non-recurring net impairment charges ranging from 65 to 85\(^1\) million euros

\(^1\) Non-audited figures
Ipsen recovers rights to taspoglutide

Ipsen to receive the full body of data

The data will be carefully assessed to determine potential partnership opportunities

Financial impact: Non-cash non-recurring profit of c. €41m after tax as accelerated recognition of differed revenues in 2010 accounts

We will provide further visibility on the next step in the future

Ipsen has no intention to clinically develop taspoglutide on its own
Inspiration announces non-inferiority of IB1001

Ipsen’s partner Inspiration Biopharmaceuticals presented Pharmacokinetic results of IB1001

IB1001 demonstrated non-inferiority to BeneFIX®, the only approved recombinant FIX product…

…emphasizing the encouraging medical potential of IB1001

IB1001 Phase 3 safety and efficacy results expected later this year
Key take-aways

2010 Drug Sales in line with objectives

Positive trends underpin the core strengths of Ipsen

- International footprint
- Strong momentum in emerging markets
- Excellent and differentiated Specialty care portfolio
- A number of WW and US PhIII trials (Ipsen and Inspiration)
- World class management team and scientists

2010 results to be impacted by non cash and non recurring amounts

More to come:

March 2, 2011: full year 2010 results

2nd quarter of 2011: Investor day
Thank you

February 3, 2011